Skip to main content
PharmSpace

Class Explorer · Endocrine

Sulfonylureas

Close the ATP-sensitive potassium channel on the beta cell, depolarising it and forcing insulin release whether or not glucose is high. That last clause is the whole safety story.

Members

Also in this class: Glimepiride · Glipizide. Full pages arrive as the library grows.

Compare the members

Gliclazide
Duration
Shorter
Renal behaviour
Inactive metabolites, more forgiving
Note
Preferred if a sulfonylurea is needed
Glyburide (glibenclamide)
Duration
Long
Renal behaviour
Active renal metabolites accumulate
Note
Avoid in older adults and CKD

Shared across the class

Indications
Type 2 diabetes, second-line or where cost dominates
Adverse effects
Hypoglycemia · Weight gain
Contraindications
Type 1 diabetes · Severe renal or hepatic impairment (agent-dependent)
Monitoring
Hypoglycemia symptoms and, if capillary testing is available, values · HbA1c · Renal function, which changes the hypoglycemia risk of the same dose

What makes each agent different

  • Glyburide has active renally-cleared metabolites and the longest duration: in an older patient with declining kidneys it is a hypoglycemia engine, and most geriatric prescribing lists name it explicitly as one to avoid.
  • Gliclazide is shorter-acting with inactive metabolites and is the sensible choice when a sulfonylurea is genuinely needed.
  • Unlike metformin, SGLT2 inhibitors and GLP-1 agonists, no sulfonylurea has shown cardiovascular benefit; they lower glucose and nothing more.

A sulfonylurea taken with a skipped meal is a hypoglycemia waiting for a schedule. Sick-day rules matter as much here as with metformin.

Sulfonylurea hypoglycemia is long. A patient who wakes up with glucose and a sandwich has not been treated, they have been postponed, and they need admission and an infusion.

Last reviewed 2026-08-16 · Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.